TR201908522T4 - Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. - Google Patents

Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. Download PDF

Info

Publication number
TR201908522T4
TR201908522T4 TR2019/08522T TR201908522T TR201908522T4 TR 201908522 T4 TR201908522 T4 TR 201908522T4 TR 2019/08522 T TR2019/08522 T TR 2019/08522T TR 201908522 T TR201908522 T TR 201908522T TR 201908522 T4 TR201908522 T4 TR 201908522T4
Authority
TR
Turkey
Prior art keywords
hydroxybutyrate
compositions
ketone
racemic
blood lipid
Prior art date
Application number
TR2019/08522T
Other languages
English (en)
Inventor
Clarke Kieran
Lewis Veech Richard
Original Assignee
The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services, Univ Oxford Innovation Ltd filed Critical The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services
Publication of TR201908522T4 publication Critical patent/TR201908522T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Hastalarda serum kolesterolü ve/veya trigliserit seviyelerini düşüren bileşimler sunulmaktadır. Bileşimler rasemik ?-hidroksibütirat veya D-?-hidroksibütirat (isteğe bağlı olarak asit formunda), rasemik ?-hidroksibütirat veya D-?-hidroksibütiratın fizyolojik olarak uyumlu tuzları, D-?-hidroksibütirat esterleri, doğrusal veya siklik formda 2 ila 20 veya daha fazla monomerik birim içeren D-?-hidroksibütirat oligomerleri, rasemik 1,3-bütandiol veya R-1,3 bütandiolü tek başına içerebilir ve bir hastaya düşük yağ içerikli bir diyetle birlikte uygulanabilir. Bileşimler besin takviyeleri olarak formüle edilebilir veya a) antihipertansif; b) antienflamatuvar; c) glukoz düşürücü; veya d) antilipemik maddeler içeren terapötik bileşimlere dâhil edilebilir. Açıklanan bileşimler damar hastalığını önlemek veya tersine çevirmek için tek başlarına veya başka terapötik maddelerle birlikte de uygulanabilir.
TR2019/08522T 2008-01-04 2009-01-05 Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. TR201908522T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1896208P 2008-01-04 2008-01-04

Publications (1)

Publication Number Publication Date
TR201908522T4 true TR201908522T4 (tr) 2019-07-22

Family

ID=40853425

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08522T TR201908522T4 (tr) 2008-01-04 2009-01-05 Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri.

Country Status (8)

Country Link
US (4) US9211275B2 (tr)
EP (1) EP2240017B1 (tr)
CN (2) CN101969769A (tr)
AU (1) AU2009204370B2 (tr)
DK (1) DK2240017T3 (tr)
ES (1) ES2730879T3 (tr)
TR (1) TR201908522T4 (tr)
WO (1) WO2009089144A1 (tr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108740A2 (en) 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
TR201908522T4 (tr) 2008-01-04 2019-07-22 The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri.
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
AU2013337308B2 (en) * 2012-11-05 2018-06-21 Tdeltas Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
BR112015023334B1 (pt) 2013-03-14 2021-05-18 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services processo para produção de (r)-3hidroxibutil (r)-3-hidroxibutirato
CA2902603C (en) 2013-03-19 2021-03-02 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
US20150199491A1 (en) * 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
JP6721583B2 (ja) 2014-07-21 2020-07-15 オウルン イリオピストＯｕｌｕｎ Ｙｌｉｏｐｉｓｔｏ ３−ヒドロキシブチラートのオリゴマー体
CN104940181B (zh) * 2015-06-29 2018-02-16 齐锦生 β‑羟丁酸或其药学上可接受的盐的用途
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US20170266147A1 (en) * 2016-03-18 2017-09-21 Csilla Ari D'Agostino Methods of increasing latency of anesthetic induction using ketone supplementation
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
GB201616058D0 (en) * 2016-09-21 2016-11-02 Chain Biotechnology Ltd Probiotic composition
US20180125812A1 (en) 2016-11-04 2018-05-10 Emory University Dehydroacetic Acid (DHAA) and Derivative for Uses in Treating Cancer
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
CA3053663C (en) * 2017-04-12 2021-09-07 Franco CAVALERI Butyrate and beta-hydroxybutyrate compositions and methods of use thereof
CN107083406B (zh) * 2017-05-27 2021-02-02 浙江华睿生物技术有限公司 (r)-3-羟基丁酸的生产方法
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
WO2019035486A1 (ja) * 2017-08-18 2019-02-21 拓己 佐藤 血糖値スパイク抑制剤、食品及び血糖値スパイク抑制剤の製造方法
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
AU2019282691A1 (en) 2018-06-05 2020-12-24 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
GB2577723A (en) 2018-10-04 2020-04-08 Tdeltas Ltd Compounds for new use
EP3923924A4 (en) * 2019-02-11 2022-11-09 Axcess Global Sciences, LLC NON-RACEMIC BETA-HYDROXYBUTYRATE COMPOUNDS AND R-ENANTIOMER ENRICHED COMPOSITIONS AND METHODS OF USE
CN113660930A (zh) * 2019-02-11 2021-11-16 阿克塞斯全球科学有限责任公司 β-羟基丁酸盐混合盐-酸组合物和使用方法
CN109806251A (zh) * 2019-03-04 2019-05-28 清华大学 3-羟基丁酸及其衍生物在制备抗动脉粥样硬化的产品中的应用
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
CN110776425B (zh) * 2019-10-23 2021-02-26 清华大学 一种(r)-3-羟基丁酸及其低聚物的制备方法
GB201918657D0 (en) 2019-12-17 2020-01-29 Tdeltas Ltd Compounds for new use
AU2022315496A1 (en) * 2021-07-17 2023-12-07 Ketoswiss Ag Combination of a ketone body or ketogenic compound with an analgesic or antioxidant
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU507322A1 (ru) 1973-07-26 1976-03-25 Московский Научно-Исследовательский Институт Косметологии Регул тор гормонального обмена кожи
US3984566A (en) 1974-02-25 1976-10-05 Scott Eugene J Van Method of alleviating the symptoms of dandruff
IT1051853B (it) 1975-01-07 1981-05-20 Basf Ag Butandiol 1.3 3 mono 3 idros sibutirrati butandiol 1.3 1mono 3 idrossibutirrati e processi per la loro preparazione
US4380549A (en) 1975-07-23 1983-04-19 Scott Eugene J Van Topical treatment of dry skin
JPS54138126A (en) 1978-04-17 1979-10-26 Ajinomoto Co Inc Remedy for diabetes
AU6777487A (en) 1985-12-18 1987-07-15 Veech, R.L. Parenteral nutrition therapy with amino acids
JPH0755158B2 (ja) 1986-10-30 1995-06-14 チッソ株式会社 光学活性エステルの製造法
JP2579779B2 (ja) 1987-10-08 1997-02-12 日本車輌製造株式会社 飼料の製造法
BE1001209A3 (fr) 1987-11-19 1989-08-22 Solvay Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
JPH0383950A (ja) 1989-08-28 1991-04-09 Kanegafuchi Chem Ind Co Ltd グリセリド誘導体およびその製造法
JP2873497B2 (ja) 1990-09-03 1999-03-24 理化学研究所 脂質代謝調節剤
JP2884123B2 (ja) 1992-01-17 1999-04-19 高砂香料工業株式会社 生分解性光学活性ポリマー、その中間体オリゴマー、およびそれらの製造方法
US5654266A (en) 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
US5281691A (en) 1992-06-19 1994-01-25 Eastman Kodak Company Poly(3-hydroxyalkanoates)
JP3193542B2 (ja) 1993-09-08 2001-07-30 カネボウ株式会社 皮膚老化防止化粧料
WO1995009144A1 (en) 1993-09-30 1995-04-06 Eastman Chemical Company Nutritive water soluble glycerol esters of hydroxy butyric acid
DE59508729D1 (de) 1994-08-10 2000-10-26 Peter Neuenschwander Biokompatibles Blockcopolymer
US6306828B1 (en) 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US6126953A (en) 1996-08-19 2000-10-03 The Procter & Gamble Company Fragrance delivery systems for personal care articles
JPH10175855A (ja) 1996-10-16 1998-06-30 Taisho Pharmaceut Co Ltd 肉体疲労改善剤
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
KR100839689B1 (ko) 1997-03-17 2008-06-18 비티지 인터내셔널 리미티드 치료용 조성물
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
JPH10265378A (ja) 1997-03-25 1998-10-06 Ofutekusu:Kk 角膜上皮損傷治療剤
ATE359071T1 (de) 1997-05-15 2007-05-15 Univ Washington Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen
US6727258B2 (en) 1997-10-29 2004-04-27 King Pharmaceutical Research & Development, Inc. Allosteric adenosine receptor modulators
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
AU755348B2 (en) 1998-07-22 2002-12-12 Cj Cheiljedang Corporation Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers
RU2242227C2 (ru) * 1998-09-15 2004-12-20 Би Ти Джи Интернэшнл Лимитед Терапевтические композиции (ii)
AU6988100A (en) 1999-08-20 2001-03-19 Unilever Plc A method for reducing skin irritation and sting from weak carboxylic acid
PT1248849E (pt) 2000-01-14 2008-09-08 Serono Genetics Inst Sa Cabeça globular obg3 e suas utilizações para reduzir a massa corporal
ES2323940T3 (es) 2000-05-01 2009-07-28 Accera, Inc. Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer.
EP2275468A1 (en) 2000-07-14 2011-01-19 Metabolix, Inc. Polyurethanes obtained from hydroxyalkanoates and isocyanates
AUPR177300A0 (en) 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
US20050129783A1 (en) 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
DE20205184U1 (de) 2002-03-27 2002-12-19 Bartz Volker Blutfettsenker zur oralen Einnahme
CN1483355A (zh) 2002-09-16 2004-03-24 岚 高 抗疲劳饮料配方
EP1641444B1 (en) 2003-06-02 2016-03-23 Isis Innovation Limited Treatment of muscle fatigue
WO2004108740A2 (en) * 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
JP2005247821A (ja) 2004-02-06 2005-09-15 Ophtecs Corp 炎症性サイトカインの産生を抑制するための眼科用組成物
DE102004007029A1 (de) 2004-02-12 2005-09-08 Consortium für elektrochemische Industrie GmbH Verfahren zur enantioselektiven Reduktion von Ketoverbindungen durch Enzyme
US7947736B2 (en) 2004-07-16 2011-05-24 Btg International Limited Oligomeric compounds
EP1778615A4 (en) * 2004-07-20 2010-01-06 Btg Int Ltd OLIGOMERE KETONE COMPOUNDS
WO2006012490A2 (en) * 2004-07-23 2006-02-02 Ketocytonyx Inc. Ketogenic saccharides
US8124063B2 (en) 2004-10-25 2012-02-28 Conopco, Inc. Method for moisturizing human skin using dihydroxypropyltri(C1-C3 alkyl) ammonium salts
ITTO20040918A1 (it) 2004-12-29 2005-03-29 Luigi Ambrosio Idrogel polimerici superassorbenti biodegradabili e procedimento per la loro preparazione
US20070135376A1 (en) 2005-06-20 2007-06-14 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
ES2338704T3 (es) 2005-11-29 2010-05-11 Basf Se Procedimiento para la transesterificacion o para la esterificacion de cadenas laterales en polimeros.
HUE040002T2 (hu) 2006-04-03 2019-02-28 Accera Inc Ketogén vegyületek alkalmazása korfüggõ memóriazavar kezelésére
CN101466362A (zh) 2006-04-12 2009-06-24 荷兰联合利华有限公司 对皮肤具有抗老化效果的口服组合物
US7807718B2 (en) 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
JP5030553B2 (ja) 2006-11-24 2012-09-19 有限会社ノーベル医学研究所 ドライマウスおよび／または唾液分泌障害を処置するための医薬
WO2008119032A1 (en) 2007-03-27 2008-10-02 Perscitus Biosciences, Llc Compositions and methods for protecting cells from toxic exposures
CN101795701A (zh) 2007-05-14 2010-08-04 纽尔雅制药公司 用于治疗神经元代谢减退的乙酰coa羧化酶抑制剂
WO2009023357A2 (en) 2007-05-25 2009-02-19 University Of Rochester Curcumin derivatives and their use as radioprotectors
TR201908522T4 (tr) 2008-01-04 2019-07-22 The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri.
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
EP3296284B1 (en) 2008-08-21 2021-12-01 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Non-therapeutical use of hydroxybutyrate ester
WO2010120300A1 (en) 2009-04-16 2010-10-21 Isis Innovation Limited Process for the preparation of (3r)-hydr0xybutyl (3r) -hydroxybutyrate by enzymatic enantioselective reduction employing lactobacillus brevis alcohol dehydrogenase
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
FR2958154B1 (fr) 2010-04-01 2012-06-08 Oreal Procede de soin et/ou de maquillage des rides
KR20140008394A (ko) 2011-02-17 2014-01-21 시에이치디 바이오사이언스 인코포레이티드 퍼옥시 α-케토카르복실산을 포함하는 조성물 및 이를 생산하고 사용하기 위한 방법
WO2012113415A1 (en) 2011-02-24 2012-08-30 N.V. Nutricia Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
GB201206192D0 (en) 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
AU2013337308B2 (en) 2012-11-05 2018-06-21 Tdeltas Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
BR112015023334B1 (pt) 2013-03-14 2021-05-18 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services processo para produção de (r)-3hidroxibutil (r)-3-hidroxibutirato
GB201314127D0 (en) 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown

Also Published As

Publication number Publication date
CN106038532A (zh) 2016-10-26
EP2240017B1 (en) 2019-03-13
CN101969769A (zh) 2011-02-09
EP2240017A4 (en) 2011-02-16
ES2730879T3 (es) 2019-11-13
US20160193173A1 (en) 2016-07-07
WO2009089144A1 (en) 2009-07-16
CN106038532B (zh) 2019-05-14
AU2009204370B2 (en) 2014-12-04
US9211275B2 (en) 2015-12-15
EP2240017A1 (en) 2010-10-20
US20190201366A1 (en) 2019-07-04
DK2240017T3 (da) 2019-06-17
US20230075547A1 (en) 2023-03-09
AU2009204370A1 (en) 2009-07-16
US20100298294A1 (en) 2010-11-25
US11311509B2 (en) 2022-04-26
US10154982B2 (en) 2018-12-18

Similar Documents

Publication Publication Date Title
TR201908522T4 (tr) Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri.
Sun et al. Oleuropein, unexpected benefits!
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
MX2011007544A (es) Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso.
WO2003022288A1 (fr) Compositions nutritionnelles permettant de reguler le niveau de glucose sanguin
ZA200909230B (en) Improving memory in subjects with mini-mental state examination of 24-26
MY150595A (en) Nutritional composition to promote healthy development and growth
ES2571856T3 (es) Uso de composiciones nutricionales para prevenir la adiposidad visceral
JP2009528833A5 (tr)
MY167583A (en) Infant formula with high sn-2 palmitate and oligofructose
MX2009001156A (es) Composiciones de vitamina d y metodo de administracion a un ser humano.
BR112013025047A2 (pt) composições nutricionais para aumentar os níveis de arginina e métodos para usar as mesmas
NZ608292A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
WO2007038641A3 (en) Methods and therapies for treating inflammatory conditions with exposed collagen
HK1129071A1 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
WO2007005774A3 (en) Novel derivatives of amino acids for treatment of obesity and related disorders
WO2006102643A3 (en) Stably transformed bone marrow-derived cells and uses thereof
AR046454A1 (es) Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica
US9987243B2 (en) Use of trans-palmitoleate in identifying and treating metabolic disease
TR200704897A1 (tr) Uzatılmış salım sağlayan gliklazid formülasyonları@
US20130029996A1 (en) Special composition for the use thereof as a drug
JP5734134B2 (ja) 抗疲労用医薬組成物
TW200738654A (en) Alkoxymethyl-substituted benzoic acid derivatives, process for their preparation and their use as medicaments
HRP20050738A2 (en) Cycloalkyl derivatives comprising bioisosteric carboxylic acid groups, method for the production thereof, and use thereof as a medicament